Display options
Cite
Blum CA, Mueller C, Schuetz P, et al. Prognostic value of dehydroepiandrosterone-sulfate and other parameters of adrenal function in acute ischemic stroke. PLoS One. 2013;8(5):e63224doi: 10.1371/journal.pone.0063224.
Blum, C. A., Mueller, C., Schuetz, P., Fluri, F., Trummler, M., Mueller, B., Katan, M., & Christ-Crain, M. (2013). Prognostic value of dehydroepiandrosterone-sulfate and other parameters of adrenal function in acute ischemic stroke. PloS one, 8(5), e63224. https://doi.org/10.1371/journal.pone.0063224
Blum, Claudine A, et al. "Prognostic value of dehydroepiandrosterone-sulfate and other parameters of adrenal function in acute ischemic stroke." PloS one vol. 8,5 (2013): e63224. doi: https://doi.org/10.1371/journal.pone.0063224
Blum CA, Mueller C, Schuetz P, Fluri F, Trummler M, Mueller B, Katan M, Christ-Crain M. Prognostic value of dehydroepiandrosterone-sulfate and other parameters of adrenal function in acute ischemic stroke. PLoS One. 2013 May 01;8(5):e63224. doi: 10.1371/journal.pone.0063224. Print 2013. PMID: 23650556; PMCID: PMC3641134.
Copy Download .nbib Format: NLM
Share it on

PLoS One. 2013 May 01;8(5):e63224. doi: 10.1371/journal.pone.0063224. Print 2013.

Prognostic value of dehydroepiandrosterone-sulfate and other parameters of adrenal function in acute ischemic stroke.

PloS one

Claudine A Blum, Cornelia Mueller, Philipp Schuetz, Felix Fluri, Michael Trummler, Beat Mueller, Mira Katan, Mirjam Christ-Crain

Affiliations

  1. Department of Endocrinology, Medical University Clinic, Cantonal Hospital, Aarau, Switzerland. [email protected]

PMID: 23650556 PMCID: PMC3641134 DOI: 10.1371/journal.pone.0063224

Abstract

BACKGROUND AND PURPOSE: Acute stroke has a high morbidity and mortality. We evaluated the predictive value of adrenal function testing in acute ischemic stroke.

METHODS: In a cohort of 231 acute ischemic stroke patients, we measured dehydroepiandrosterone (DHEA), DHEA-Sulfate (DHEAS), cortisol at baseline and 30 minutes after stimulation with 1 ug ACTH. Delta cortisol, the amount of rise in the 1 ug ACTH-test, was calculated. Primary endpoint was poor functional outcome defined as modified Rankin scale 3-6 after 1 year. Secondary endpoint was nonsurvival after 1 year.

RESULTS: Logistic regression analysis showed that DHEAS (OR 1.21, 95% CI 1.01-1.49), but not DHEA (OR 1.01, 95% CI 0.99-1.04), was predictive for adverse functional outcome. Neither DHEA (OR 0.99, 95% CI 0.96-1.03) nor DHEAS (OR 1.10, 95% CI 0.82-1.44) were associated with mortality. Baseline and stimulated cortisol were predictive for mortality (OR 1.41, 95% CI 1.20-1.71; 1.35, 95% CI 1.15-1.60), but only basal cortisol for functional outcome (OR 1.20, 95% CI 1.04-1.38). Delta cortisol was not predictive for functional outcome (OR 0.86, 95% CI 0.71-1.05) or mortality (OR 0.92, 95% CI 0.72-1.17). The ratios cortisol/DHEA and cortisol/DHEAS discriminated between favorable outcome and nonsurvival (both p<0.0001) and between unfavorable outcome and nonsurvival (p = 0.0071 and 0.0029), but are not independent predictors for functional outcome or mortality in multivariate analysis (adjusted OR for functional outcome for both 1.0 (95% CI 0.99-1.0), adjusted OR for mortality for both 1.0 (95% CI 0.99-1.0 and 1.0-1.01, respectively)).

CONCLUSION: DHEAS and the cortisol/DHEAS ratio predicts functional outcome 1 year after stroke whereas cortisol levels predict functional outcome and mortality.

TRIAL REGISTRATION: ClinicalTrials.gov NCT00390962 (Retrospective analysis of this cohort).

References

  1. Lancet. 1991 Jun 22;337(8756):1521-6 - PubMed
  2. J Clin Endocrinol Metab. 1971 Jul;33(1):87-92 - PubMed
  3. Biol Pharm Bull. 2004 Oct;27(10):1489-96 - PubMed
  4. J Cereb Blood Flow Metab. 2009 Feb;29(2):287-96 - PubMed
  5. J Clin Endocrinol Metab. 2005 Aug;90(8):4579-86 - PubMed
  6. Eur J Neurol. 2006 Jun;13(6):581-98 - PubMed
  7. J Clin Endocrinol Metab. 1985 May;60(5):947-52 - PubMed
  8. Crit Care Med. 2001 May;29(5):965-70 - PubMed
  9. Eur J Endocrinol. 2010 May;162(5):919-23 - PubMed
  10. Crit Care Med. 2008 Jun;36(6):1937-49 - PubMed
  11. J Clin Endocrinol Metab. 2010 Nov;95(11):4985-92 - PubMed
  12. N Engl J Med. 1986 Dec 11;315(24):1519-24 - PubMed
  13. Brain Cogn. 2002 Nov;50(2):316-23 - PubMed
  14. Eur J Endocrinol. 2010 Aug;163(2):285-92 - PubMed
  15. Acta Cardiol. 2003 Oct;58(5):403-10 - PubMed
  16. N Engl J Med. 2004 Apr 15;350(16):1629-38 - PubMed
  17. Arq Bras Endocrinol Metabol. 2011 Jun;55(5):295-302 - PubMed
  18. J Neurol Sci. 2002 Apr 15;196(1-2):27-32 - PubMed
  19. Psychoneuroendocrinology. 2005 Feb;30(2):121-8 - PubMed
  20. N Engl J Med. 2003 Feb 20;348(8):727-34 - PubMed
  21. Crit Care Med. 2003 May;31(5):1382-8 - PubMed
  22. Stroke. 2004 Aug;35(8):1941-5 - PubMed
  23. Acta Paediatr Suppl. 1999 Dec;88(433):78-80 - PubMed
  24. J Neurotrauma. 2009 Sep;26(9):1435-46 - PubMed
  25. Scott Med J. 1957 May;2(5):200-15 - PubMed
  26. Eur J Endocrinol. 2010 Feb;162(2):341-7 - PubMed
  27. Ann Neurol. 2009 Dec;66(6):799-808 - PubMed
  28. J Clin Endocrinol Metab. 2006 Jul;91(7):2548-54 - PubMed
  29. Stroke. 2010 Jul;41(7):1564-7 - PubMed
  30. Lancet. 2007 Oct 20;370(9596):1453-7 - PubMed
  31. J Neurol Sci. 2004 Feb 15;217(2):175-80 - PubMed
  32. Proc Natl Acad Sci U S A. 1981 Aug;78(8):4704-7 - PubMed
  33. Neuroendocrinology. 1999 Dec;70(6):431-8 - PubMed
  34. Eur Respir J. 2010 Sep;36(3):615-21 - PubMed
  35. C R Biol. 2007 Oct;330(10):755-63 - PubMed
  36. Crit Care. 2002 Oct;6(5):434-8 - PubMed
  37. Curr Neurovasc Res. 2007 Aug;4(3):170-5 - PubMed
  38. J Neurol Sci. 1997 Mar 20;147(1):43-7 - PubMed
  39. J Am Geriatr Soc. 2010 Mar;58(3):421-6 - PubMed
  40. J Endocrinol Invest. 2004;27(6 Suppl):62-3 - PubMed
  41. Bull World Health Organ. 1976;54(5):541-53 - PubMed
  42. Neuroimmunomodulation. 2010;17(1):9-18 - PubMed
  43. Lancet. 2012 Dec 15;380(9859):2197-223 - PubMed
  44. J Crit Care. 2010 Sep;25(3):541.e1-8 - PubMed
  45. Brain Res Brain Res Rev. 1999 Nov;30(3):264-88 - PubMed
  46. J Clin Endocrinol Metab. 2000 Oct;85(10):3561-8 - PubMed
  47. JAMA. 1977 Sep 26;238(13):1374-6 - PubMed
  48. Intensive Care Med. 2004 Jun;30(6):1216-9 - PubMed
  49. Stroke. 1992 Nov;23(11):1573-6 - PubMed
  50. Endocrine. 2003 Nov;22(2):113-8 - PubMed
  51. J Clin Endocrinol Metab. 1991 Apr;72(4):773-8 - PubMed
  52. Neuroscience. 2011 Sep 15;191:22-7 - PubMed
  53. J Clin Endocrinol Metab. 2010 Sep;95(9):4406-14 - PubMed
  54. J Intensive Care Med. 2012 Feb;27(1):37-44 - PubMed
  55. Metabolism. 2012 Jan;61(1):84-91 - PubMed
  56. J Neurosci Res. 1987;17(3):225-34 - PubMed
  57. J Clin Endocrinol Metab. 2005 Aug;90(8):4973-4 - PubMed
  58. J Pediatr. 1994 Dec;125(6 Pt 1):853-7 - PubMed
  59. J Intern Med. 2011 Apr;269(4):420-32 - PubMed
  60. J Clin Endocrinol Metab. 1988 Aug;67(2):223-7 - PubMed
  61. Atherosclerosis. 2011 Jan;214(1):47-57 - PubMed
  62. Metabolism. 2012 Feb;61(2):193-201 - PubMed
  63. Acta Neurochir Suppl. 2010;106:221-4 - PubMed
  64. J Intern Med. 2004 Jul;256(1):15-21 - PubMed
  65. Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4089-91 - PubMed
  66. Synapse. 2003 Jan;47(1):10-4 - PubMed
  67. Ann Intern Med. 2006 Aug 1;145(3):176-84 - PubMed
  68. Stroke. 2000 Aug;31(8):1953-6; discussion 1957 - PubMed
  69. J Clin Endocrinol Metab. 1986 Apr;62(4):767-72 - PubMed
  70. Am J Physiol Endocrinol Metab. 2006 Feb;290(2):E234-42 - PubMed
  71. Biol Psychiatry. 2001 Mar 15;49(6):547-52 - PubMed
  72. Drug Metab Dispos. 2011 May;39(5):814-9 - PubMed

Substances

MeSH terms

Publication Types